Navigation Links
AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
Date:2/11/2008

indicates that confluent NHEK treated with OGG1 are resistant to ssUV cell death, allowing more time for DNA repair.

The second study examined the question of whether repairing the ssUV- induced DNA damage by OGG1 in the epidermal keratinocytes, would also present the by-stander effect in the fibroblasts by reducing the release of TNf-a from NHEK. For the test, dermal fibroblasts were grown for 48 hours in materials taken from the ssUV-irradiated NHEK. The ssUV-irradiated NHEK induced more MMP-1 secretion and greater collagen loss compared to direction irradiation of NHDF with the same ssUV dose. The model system was also used to investigate whether OGG1 would be effective in diminishing the detrimental effects of ssUV radiation on the underlying dermis. Treatment of ssUV-irradiated NHEK with OGG1 liposomes for 24 hours suppressed the induction of MMP-1 secretion by NHDF, as well as showed diminished collagen loss.

In conclusion, these results indicate that treatment of dermal fibroblasts and epidermal keratinocytes with OGG1 liposomes enhance DNA repair, reduces MMP-1 and increases collagen levels in the epidermis and the underlying dermis.

AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. Remergent DNA Repair Formula and Antioxidant Refoliator both contain Roxomes, liposomes encapsulating OGG1.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. '/>"/>

SOURCE AGI Dermatics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
2. New Study Indicates Decreasing Prescription Copayments Results in Increased Adherence for Patients with Chronic Diseases
3. Study Indicates Strong Consumer Preference to Fix Medicare Part D and Medicaid Flaws Threatening Access to Prescription Drugs
4. Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
5. Research Indicates Nearly 25 Percent of Supplements Are Contaminated With Steroids, Stimulants and Banned Substances
6. Study indicates pregnancy does not harm chances of survival from cancer
7. Mayo Clinic study indicates medication for ADHD may help student outcomes
8. New Research From America On the Move Foundation Indicates American Weight Loss Efforts Stalling
9. Turning on adult stem cells may help repair bone
10. Stem cells could be used for cardiac repair
11. Intensive training post-spinal cord injury can stimulate repair in brain and spinal cord
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 2Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 3Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 4Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 5Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 6Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 7Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 8Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3